To the Fullest.
Our mission is to develop and implement innovative precision medicine strategies for patients suffering from cancer. We are rooted in this purpose – extending the quality and length of life for cancer patients where we may be their best hope.
Rain’s programs focus on specific tumor genetics to meaningfully extend patients’ lives.
RAD52 Research Program
Rain’s RAD52 research program is currently in preclinical development. RAD52 plays a central role in the DNA Damage Response (DDR) pathway.
Our ultimate goal is to provide patients with effective treatment options that are not characterized by the difficult side effects that are so common with most cancer treatments.
Rain Therapeutics Presents Data on Milademetan (RAIN-32) at the 2021 AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer TherapeuticsRead more
Rain Therapeutics to Present on Milademetan at the 2021 AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer TherapeuticsRead more